Aisling Capital related stories
All articles and analysis
LENSAR raises $87 mlnLENSAR said Wednesday that it has raised $27 million in private equity financing and up to $60 million in debt financing. New investor PDL BioPharma provided the debt financing while Aisling Capital, Florida Growth and Florida Opportunity Funds invested in the equity round. Based in Orlando, Florida, LENSAR is a developer of laser systems for cataract surgery.
Fund performance: Pennsylvania's venture portfolio trumpets big gainsPortfolio sees advances in funds from LLR Partners, Psilos Group, Cross Atlantic and Aisling
- SafeStitch Medical to Merge with VC-Backed TransEnterix
SafeStitch Medical said Wednesday that it has entered into a agreement to merge with TransEnterix. According to terms of the agreement, current shareholders of SafeStitch Medical will own approximately 35% stake in the combined company while TransEnterix shareholders will own approximately 65%. The merger is expected to close in the third quarter of 2013. Perella Weinberg Partners is serving as financial advisor to TransEnterix for the transaction while Cassel Salpeter is acting as financial advisor to SafeStitch Medical. Based in Miami, Florida, SafeStitch Medical is a provider of medical devices. TransEnterix, which is backed by Aisling Capital, Intersouth Partners, Quaker BioVentures, SV Life Science Advisers, Synergy Life Science Partners and Parish Capital Advisor, is a a Morrisville, N.C.–based developer of flexible devices and robotics for minimally invasive surgery.
- ViewRay Raises Fresh $15M for Its Medical Imaging Technology
ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company's machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay's investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.
- Versartis Closes Series C Financing
Versartis, an emerging biotechnology company has completed a $25 million Series C financing lead by new investor Aisling Capital. Also participating in the round were existing investors Index Ventures, New Leaf Venture Partners and Advent Venture Partners' Advent Life Sciences fund.
- OPEN & CLOSED
OPEN & CLOSED 2009-02-01 Staff Writer OPEN & CLOSED FUNDS OPENED <
- Soros spin-out closes on $650m
Aisling Capital has closed its third fund with commitments from the New York State Teachers' Retirement System, the Pennsylvania Public School Employees’ Retirement System and the California Public Employees' Retirement System.
- New York pension backs venture funds
The fund has earmarked $80m for three venture funds, including two re-ups and one new relationship.
- CalPERS commits $500m to Blackstone
The $184bn pension, struggling with the denominator effect, committed $750m to Blackstone’s previous buyout vehicle. CalPERS documents confirmed rumours that Blackstone has lowered its fund target to between $15bn and $20bn.
- Upbeat on life sciences
Aisling Capital’s Dennis Purcell believes a change in the dynamics of the pharmaceutical industry spells good fortune for life sciences investors. By Ken MacFadyen.